Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the completion of the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at approximately $6,510,298.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Melissa Baird also recently made the following trade(s):
- On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.74, for a total transaction of $173,209.74.
- On Friday, April 5th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.58, for a total value of $171,329.58.
- On Wednesday, March 6th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $13.99, for a total value of $164,396.49.
Hims & Hers Health Stock Down 8.1 %
Biden to Drop BOMBSHELL June 13th?
From Paradigm Press | Ad
Biden’s days are numbered!
According to a former CIA and Pentagon insider…
He’s about to drop out of the presidential race on June 13th!
Click here now to see his shocking evidence.
HIMS opened at $11.25 on Friday. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $17.16. The business has a 50 day moving average of $14.01 and a 200-day moving average of $10.25. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -102.27 and a beta of 0.97.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same quarter last year, the firm posted ($0.05) EPS. The company's quarterly revenue was up 47.4% on a year-over-year basis. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Piper Sandler upped their price target on Hims & Hers Health from $9.00 to $11.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 27th. SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a "market perform" rating and a $10.00 target price for the company. Leerink Partnrs reiterated a "market perform" rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Jefferies Financial Group reissued a "hold" rating and set a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Finally, Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price objective for the company. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.85.
Read Our Latest Stock Analysis on HIMS
Institutional Trading of Hims & Hers Health
Hedge funds have recently modified their holdings of the stock. Graham Capital Management L.P. lifted its holdings in Hims & Hers Health by 39.4% during the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company's stock worth $2,141,000 after purchasing an additional 96,277 shares during the last quarter. Swiss National Bank boosted its position in shares of Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company's stock valued at $1,945,000 after acquiring an additional 26,100 shares during the period. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp increased its position in Hims & Hers Health by 11.5% during the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company's stock worth $3,551,000 after acquiring an additional 58,288 shares during the period. Finally, Must Asset Management Inc. acquired a new stake in Hims & Hers Health in the 3rd quarter worth about $1,596,000. Institutional investors and hedge funds own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
